PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10227330

Allergen immunotherapy: a long-term perspective.

R Patterson·L C Grammer
View original source ↗Export metadata ↓

Abstract

Efficacy of standard IT to reduce medications and symptoms by at least 50% has been demonstrated multiple times. Reports of negative studies of IT deserve only evaluation of why the study design failed to demonstrate efficacy. Emphasis in the US and worldwide should be on education on the appropriate use of allergen IT, improvements in IT therapy, and preparation for the increased demand for allergists-immunologists as Fellowship training programs decline in numbers and individual training slots decrease.

Explore related subjects

Desensitization, ImmunologicHypersensitivityEditorialResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Patterson, L C Grammer. 1999. Allergen immunotherapy: a long-term perspective.. https://doi.org/10.1016/s1081-1206(10)63280-2

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

[Current recommendations for the use of SCIT and SLIT].

Allergen specific immunotherapy (SIT) is the only potentially curative treatment of IgE mediated allergic diseases. To ensure its effective use, many requirements must be met before and during therapy. Before starting immunotherapy, informed consent should be obtained, along with the consideration of the indications and contraindications. SIT should be prescribed and administered only by physicians with experience in allergic disease who are qualified to manage severe anaphylactic reactions. The clinical symptoms and the age of the patients determine the route of application, choice of allergen extracts and the duration of treatment. Numerous products and protocols facilitate an individualised therapy.

Desensitization, Immunologic↗
PubMed2006

Enhancing efficacy, safety, and convenience of immunotherapy: a workshop presentation.

OBJECTIVE: To discuss issues in delivering appropriate allergen immunotherapy. DATA SOURCES: Review of Immunotherapy Collegium II workshop presented at the 2005 Annual Meeting of the American College of Allergy, Asthma and Immunology. STUDY SELECTION: Topics discussed during Immunotherapy Collegium II. RESULTS: In the past, dosage schedules, levels, and rates of acceleration were linked to skin test results. The most recent published schedules for administration of immunotherapy do not reflect the initial reaction to the skin test, but leave it to the treating physician to factor in the results of testing with plans for administration in both increments and frequency. However, there are no official recommendations for physicians relevant to using a skin test to gauge patient sensitivity. Rather, allergists are advised to set up a maintenance concentrate and then make suitable dilutions when immunotherapy is initiated. CONCLUSION: Although recommendations are lacking regarding the use of a skin test to gauge patient sensitivity, official recommendations are clear in other areas of immunotherapy, such as the use of premedication. It is important that standard terms be adopted by all physicians who prescribe allergen immunotherapy and that modified allergens and/or oral immunotherapy be explored in the future to make immunotherapy more comfortable.

Desensitization, Immunologic↗